The World Health Organization (WHO) Essential Medicines List (EML) serves as a foundational guide for global health, aiming to ensure equitable access to critical therapies. This comprehensive analysis reveals that while many essential medicines can be manufactured at remarkably low costs, their market prices frequently diverge significantly. This disparity is not merely a function of production expenses but is shaped by a complex interplay of intellectual property rights, the dynamics of global supply chains, and national healthcare policies. The resulting barriers to affordability and consistent access pose a substantial challenge to achieving universal health coverage. This report delves into the intricate components of pharmaceutical production costs, examines the multifaceted drivers of market prices, highlights the critical discrepancies observed, and concludes with strategic recommendations designed to foster greater affordability, enhance supply chain resilience, and ultimately improve global access to essential medicines.
II. Introduction to the WHO Essential Medicines List (EML)
A. Purpose, History, and Evolution of the EML
The WHO Model List of Essential Medicines (EML), first published in 1977 with 186 medicines, established a global benchmark for prioritizing healthcare needs.1 Its companion, the Essential Medicines List for Children (EMLc), was introduced in 2007.1 These lists are dynamic instruments, undergoing biennial updates by the Expert Committee on Selection and Use of Essential Medicines to reflect evolving global health priorities and pharmaceutical advancements.1 The most recent versions, the 23rd EML and 9th EMLc, were updated in July 2023.1
Essential medicines are fundamentally defined as those that “satisfy the priority health care needs of a population” and are expected to be accessible at all times, in sufficient quantities, and at affordable prices.1 This definition has evolved since the EML’s inception in 1977, when medicines were described as “of utmost importance, basic, indispensable, and necessary,” shifting to the current, more encompassing definition in 2002.2 The EML’s primary function is to serve as a guiding framework for countries and regional authorities in developing their own national essential medicines lists, with 146 countries adopting this concept by 2018.1
The continuous expansion of the EML, from its initial 186 medicines to over 500 by 2023, reflects a broadening understanding of “priority health care needs” and an increasing global health burden.2 This expansion is not merely quantitative; it includes new treatments for various cancers, insulin analogues, and advanced oral medicines for diabetes, as well as novel antimicrobials.3 These additions often represent more complex and costly therapies, such as biologics, which inherently possess different and higher cost structures compared to traditional small-molecule drugs.7 This growing number and complexity of drugs on the EML inherently escalates the challenge of ensuring affordability and access on a global scale, making comprehensive cost estimation and price negotiation increasingly intricate.
B. Selection Criteria and Categories of Essential Medicines
Medicines are selected for the EML based on rigorous criteria, including disease prevalence, robust scientific evidence of benefit, a thorough assessment of potential side effects, and a comparative analysis of cost-effectiveness against existing treatment options.2 A significant update in 2021 stipulated that the absolute medication cost should not be a barrier to inclusion if a medicine meets other selection criteria, and that cost-effectiveness differences should be evaluated specifically within therapeutic areas.2 This nuanced approach aims to guide rational prescribing and ensure a minimum set of efficacious, safe, and cost-effective medicines are available for priority health conditions.2 The Expert Committee continually updates the list to incorporate new pharmaceutical developments, address emerging global health concerns, and respond to challenges such as drug resistance patterns.4 The selection process is underpinned by a systematic assessment of the evidence base, prioritizing efficacy, safety, cost-effectiveness, and public-health relevance.4
The 2021 policy modification, which states that “medication cost should not be grounds for exclusion criteria if it meets other selection criteria” and that “cost-effectiveness differences should be evaluated within therapeutic areas” 2, represents a subtle yet profound shift in the EML’s philosophy. This means that a drug, even if expensive in absolute terms, can be included on the list if it is deemed the most cost-effective option within its specific therapeutic class. For instance, a new, high-cost cancer therapy might be preferred over older, less effective alternatives if its overall value proposition within cancer treatment is superior. This policy decision, while championing access to optimal treatments, inherently permits the inclusion of more expensive and complex drugs on the EML. This directly impacts the overall financial burden on health systems and can potentially widen the gap between the production costs and market prices for these newer, often patented, additions.
The EML is systematically organized by therapeutic area, encompassing a broad spectrum of medical needs. Key categories include Anaesthetics, Medicines for pain and palliative care, Anti-infective medicines, and Immunomodulators and antineoplastics, among many others.9 This categorization facilitates a structured approach to medicine selection and procurement globally.
Table 1: Key Categories of WHO Essential Medicines (Illustrative Examples)
EML Section (Total Medicines)
Sub-Category (Examples)
Indications
Formulations
1. Anaesthetics, preoperative medicines and medical gases (17)
General anaesthetics (Halothane, Ketamine, Oxygen)
Anaesthetics and therapeutic gases, Respiratory failure
III. Estimated Costs of Production for Essential Medicines
The estimation of drug product manufacturing costs is a complex undertaking, influenced by a multitude of factors that extend beyond simple raw material procurement. These costs encompass a wide array of expenses, including labor, specialized equipment, facility maintenance, stringent quality control measures, and adherence to intricate regulatory compliance standards.10 Achieving an optimal balance between operational efficiency and budgetary constraints presents a significant challenge for pharmaceutical companies, a challenge that intensifies with increasing production scale, evolving regulatory demands, and the integration of advanced manufacturing technologies.10
A. Key Components of Pharmaceutical Manufacturing Costs
Raw Materials and Active Pharmaceutical Ingredients (APIs) The cost of raw materials, particularly Active Pharmaceutical Ingredients (APIs) and excipients (inactive ingredients), constitutes a substantial portion of total manufacturing expenses. Their prices fluctuate significantly based on factors such as their source, chemical complexity, and required purity levels.10 These direct material costs are intrinsically linked to the production process and can profoundly influence the overall manufacturing cost.11 Strategic sourcing and meticulous supplier selection are crucial approaches to mitigating these expenses.11 The cost of raw materials is also contingent on the batch size, the country of manufacture, the supplier’s quality systems, and the nature of the relationship with the purchaser.11 API prices exhibit a wide range, from as low as US 1–US10 per kilogram for common medicines like paracetamol to over US10,000perkilogramforhighlycomplexcompoundssuchasanastrozole.[14]Excipients,whileinactive,arevitalcomponents,oftencomprisingapproximately502.63 per kilogram of Finished Pharmaceutical Product (FPP).14
Labor Costs Labor expenses typically account for 10-15% of the total manufacturing cost.10 These direct labor costs are inherently variable, directly correlating with the number of employee-days required to produce a specific batch of medication.11
Equipment and Facility Maintenance Modern pharmaceutical manufacturing necessitates substantial capital investment in highly sophisticated equipment.10 Furthermore, maintaining facilities in strict compliance with Good Manufacturing Practices (GMP) standards incurs ongoing operational costs, which generally range from 10-20% of total manufacturing expenditures.10
Quality Control and Assurance Costs (including GMP compliance) Rigorous quality control and assurance processes, encompassing extensive testing and validation, contribute significantly to both direct costs (e.g., reagents for testing) and indirect costs (e.g., the time required for product release and regulatory approval).10 Overall quality costs are estimated to be at least 25% of the total manufacturing cost.16 These costs are broadly categorized into prevention costs (e.g., staff training, process improvement), appraisal costs (e.g., inspections, audits), and the more detrimental internal and external failure costs (e.g., rework, product recalls, regulatory fines).16 For dietary supplement manufacturers, the initial setup of GMP compliance systems can range from $20,000 to $26,000, with annual maintenance costs varying between $46,000 and $184,000, depending on the size of the firm.20 While these figures pertain to supplements, they underscore the substantial financial commitment required for regulatory adherence. For pharmaceutical operations, compliance costs can consume up to 25% of the total site operating budget (excluding raw materials), potentially reaching €40 million annually for a typical medium-to-large production facility.21 Quality control and regulatory compliance (GMP) are not merely additional expenses but are deeply integrated and indispensable components of pharmaceutical production costs.10 These elements account for a substantial portion of manufacturing expenditures, ranging from 10-25% of the total manufacturing cost.10 This financial commitment highlights a critical economic principle: compromising on quality or compliance to reduce immediate costs can lead to severe long-term consequences, including product recalls, drug shortages, reputational damage, and significant legal penalties.23 The “cost of poor quality,” encompassing expenses from internal failures (e.g., scrap, rework) and external failures (e.g., customer complaints, regulatory fines), far outweighs the costs associated with prevention and appraisal.16 This reinforces the economic rationality of investing upfront in robust quality systems, as such an investment serves as a form of “insurance policy” against far more expensive downstream problems.21 Low pricing pressures on manufacturers can lead to underinvestment in quality and compliance 24, resulting in manufacturing issues and supply disruptions 25, ultimately undermining access to essential medicines. Therefore, any effort to reduce production costs must recognize the irreducible floor imposed by quality and regulatory requirements.
Overhead Expenses Overhead expenses typically constitute 15-20% of total manufacturing costs, varying with the size and scale of operations.10 These indirect costs include administrative functions, marketing efforts, and distribution logistics.26 The costs associated with secondary packaging materials are also categorized under distribution overheads.11
Table 2: Breakdown of Pharmaceutical Manufacturing Cost Components (Illustrative Percentages)
Cost Component
Typical Percentage of Total Manufacturing Cost
Raw Materials (APIs & Excipients)
Highly variable, often dominant
Labor
10-15% 10
Equipment and Facility Maintenance (including GMP compliance)
Note: Percentages can vary significantly based on drug type, complexity, scale, and specific manufacturing processes. Quality Control and Assurance costs are often embedded within other categories but are presented separately here to emphasize their significance.
B. Cost Variations by Drug Type: Small Molecules vs. Biologics
The pharmaceutical landscape is broadly characterized by two distinct drug types, each with unique manufacturing cost profiles: small molecules and biologics.
Small Molecules The manufacturing process for small molecules is comparatively straightforward, relying on controlled chemical reactions in laboratory settings. This allows for consistent and scalable production within standard manufacturing facilities.8 While the research and development (R&D) phase for small molecules typically requires substantial upfront investment, ranging from US$1-2 billion over 8-10 years, their subsequent manufacturing costs are relatively modest.8 The predictability of their production and inherent stability generally translate into lower treatment costs for patients.8
Biologics In stark contrast, the manufacturing of biologics is a highly complex endeavor, often described as more “art than assembly line”.8 These therapies are produced in living cells, such as Chinese Hamster Ovary (CHO) cells, under meticulously controlled conditions that demand stringent oversight of temperature, pH, and nutrient levels.8 Even minor deviations can compromise the final product’s safety and efficacy. This complexity necessitates specialized manufacturing facilities, which can cost upwards of 500milliontoconstruct.[8]Thedevelopmentofbiologicsisalsomoreresource−intensive,averagingUS2-4 billion and taking 10-12 years, although they often exhibit higher success rates in clinical trials compared to small molecules.8 Consequently, the manufacturing costs for biologics are significantly higher; the average production cost per pack for biologics is approximately $60, in sharp contrast to $5 for small molecules.7 The specialized facilities and expertise required for biologic manufacturing inherently drive up these production costs.8
The significantly higher production costs and inherent manufacturing complexity of biologics compared to small molecules 7 present a growing challenge for the WHO Essential Medicines List. As the EML continues to expand its scope to include more advanced treatments, such as new therapies for various cancers and other complex conditions 3, it increasingly incorporates biologics (e.g., Adalimumab, Rituximab, listed under Immunomodulators and Antineoplastics).9 This structural shift in the EML’s composition means that the average cost of producing and procuring essential medicines will inevitably rise. Traditional cost-reduction strategies, often focused on promoting generic small molecules, may prove insufficient to ensure broad and affordable access to these newer, more complex essential therapies. The inclusion of biologics on the EML, while clinically beneficial and often representing the best available treatment, introduces a new tier of production cost that fundamentally alters the overall cost profile of the list. This implies that achieving “affordable access” in the future will require more sophisticated and potentially higher-investment strategies than those historically applied to basic generics, as the underlying cost structure for a growing segment of essential medicines is inherently elevated.
C. Impact of Manufacturing Scale and Advanced Technologies
Scale Effects The scale of pharmaceutical manufacturing significantly impacts production costs, with larger operations generally achieving greater efficiencies. Company size plays a substantial role in cost performance, demonstrating a 15% reduction in unit cost for every doubling of total production volume.7 Similarly, larger production sites exhibit improved cost performance, with a 17% reduction in unit cost for every doubling of site size.7 Product volume is an even more potent driver of cost reduction, as unit costs can fall by as much as 29% for each doubling of product volume.7 This phenomenon reinforces the economic advantages of the “blockbuster model,” where high-volume production of a single drug yields substantial cost efficiencies.7 Furthermore, strategic mergers and acquisitions can lead to significant manufacturing cost savings by increasing overall production volume and leveraging economies of scale across combined operations.7
Advanced Technologies (Continuous Manufacturing) The adoption of advanced manufacturing technologies, such as continuous manufacturing processes, offers a transformative pathway to enhanced efficiency and cost savings compared to traditional batch processing methods.27 Continuous processing can boost production output by approximately 20% while simultaneously reducing energy consumption by 20%.28 This technology requires significantly smaller equipment and facilities—often more than ten times smaller than those needed for batch processing—thereby reducing both initial capital outlay and ongoing running costs.28 Its inherent modularity allows for greater agility in manufacturing lines, making them more adaptable to the production of new products or variations.28 Ultimately, continuous manufacturing promises lower production costs, higher and more reproducible product quality, and superior productivity through more efficient use of equipment and space.29 However, the widespread adoption of these advanced technologies faces notable challenges. These include technological hurdles, concerns related to quality and regulatory compliance, economic shortcomings, and a general aversion to risk within the pharmaceutical industry.29 This creates a paradox: while continuous manufacturing and other advanced technologies offer significant potential for long-term cost reduction and improved supply chain efficiency 27, their implementation is often slow. The high upfront capital investment required, coupled with the complex regulatory landscape and the industry’s inherent risk aversion (driven by substantial R&D reinvestment, high failure rates, and long time-to-market for new drugs) 29, creates significant barriers. This delay means that many essential medicines continue to be produced using less efficient, traditional batch processes, thereby maintaining higher production costs than what is technologically feasible. This situation underscores a critical area for policy intervention: encouraging de-risking mechanisms or providing direct incentives for manufacturers to invest in these transformative technologies to truly enhance the affordability and stability of essential medicine supplies.
D. Geographical Variations in Production Costs
The globalization of pharmaceutical supply chains has led to a significant concentration of production, particularly for Active Pharmaceutical Ingredients (APIs) and generic finished products, in a limited number of geographical regions.30 This trend is primarily driven by the pursuit of economies of scale, less stringent regulatory environments, and overall lower production costs in these regions.30 Manufacturing costs in countries like China, India, and Mexico are, on average, 30-50% lower than those in the United States.30
Comparing India and the US/China, India stands out as a major player in the generic pharmaceutical industry, holding historical importance for API procurement and Finished Pharmaceutical Product (FPP) formulation.14 Indian manufacturers also possess extensive experience with the WHO prequalification program, an initiative that certifies medicine quality.14 Quantitative data reveal substantial cost advantages in India: API Capital Expenditure (CAPEX) and Operational Expenditure (OPEX) for India-destined products are 32-37% lower than for US-destined products.31 Specifically, building costs for Indian facilities are 49.9% lower than in the US, and analytical development laboratory equipment and validation costs are remarkably lower by 78.5% and 80.0%, respectively.31 Personnel costs for API development are 63.8% lower in India, and for manufacturing, 47.1% lower than in the US.31 Even quality control costs for India-destined manufacturing are 51.2% lower than for the US market.31 Furthermore, India’s labor costs are significantly lower than China’s, with average monthly wages for factory workers ranging from $150-$300 in India compared to over $600 in many Chinese industrial zones.32 India specializes in pharmaceuticals and IT hardware manufacturing.32
Conversely, China plays a pivotal role, particularly in advanced manufacturing, and can price APIs 35-40% below Western competitors while maintaining FDA/EMA quality standards.33 China is a leading global producer and exporter of APIs, accounting for approximately one-third of the world’s supply.34 Chinese companies are often able to operate faster and at lower costs due to reduced staffing and supply chain expenses.35 Producing medicines in the US is generally more expensive than importing them from China.34 A significant decoupling of the US pharmaceutical industry from China could potentially raise costs for American drug companies by about 50%.34 The US relies heavily on lower-cost manufacturing in India and China for generic drugs, where labor costs are cheaper and profit margins for drugmakers are typically lower.36
The pursuit of the lowest production costs has led to a significant geographic concentration of pharmaceutical manufacturing, particularly for APIs and generic finished products, in countries like India and China.24 While this strategy undeniably optimizes cost efficiency, it simultaneously creates profound vulnerabilities within the global supply chain.24 Disruptions in these concentrated regions—whether caused by natural disasters, geopolitical tensions, trade policies such as tariffs, or manufacturing quality issues—can lead to widespread and prolonged drug shortages, especially for essential, low-margin generics.24 This situation highlights a critical trade-off: the short-term cost savings achieved through global concentration often come at the expense of long-term supply chain resilience and consistent patient access. The economic benefits of offshoring are thus counterbalanced by increased supply chain risk and reduced national resilience in medicine supply, posing a significant threat to global health security and the reliable availability of essential medicines.
Table 3: Comparative API and Manufacturing Costs: US vs. India (Quantitative Data)
Cost Category (API Development & Manufacturing)
US-Destined Products (Average Cost)
India-Destined Products (Average Cost)
Percentage Reduction (India vs. US) 31
API CAPEX (Total)
$2,280K
$677K
70.3%
Building Costs
–
–
49.9%
Analytical Development Lab (ADL) Equipment
–
–
78.5%
Qualification and Validation
–
–
80.0%
API Manufacturing CAPEX
–
–
28.5%
Land Acquisition
$2,021K (for India)
$2,021K (for India)
12.2% lower (for India)
API Plants (incl. pilot plants)
–
$4,997K (for India)
42.1% lower (for India)
Quality Control Costs
$1,490K
$727K
51.2%
API OPEX (Total)
–
–
32-37%
Personnel Costs (Development)
$665K
$241K
63.8%
Personnel Costs (Manufacturing)
$2,102K
$1,112K
47.1%
Repairs and Maintenance
–
$382K (for India)
26.8% lower (for India)
Consumables
–
–
32.3%
Welfare Costs
–
–
33.9%
Source:.31 Note: Specific dollar values for US-destined products were not always provided in the snippet for direct comparison, but the percentage reductions for India-destined products relative to US-destined products were explicitly stated.
IV. Analysis of Potential Prices and Price Discrepancies
A. Discrepancies Between Estimated Production Costs and Market Prices
Despite the foundational principle of the WHO Essential Medicines List (EML) being affordability and access, persistent gaps exist, with high prices often acting as a significant barrier to the utilization of these critical therapies in many settings.14 Research indicates that a substantial range of EML medicines can be profitably manufactured at very low costs; for instance, estimated generic prices have been found to range from as little as US
0.01toUS1.45 per unit.14
However, a concerning reality is that most EML medicines are sold in countries like the UK and South Africa at prices significantly exceeding their estimated production costs.14 In the UK, 77% of comparable EML items exhibited market prices higher than their estimated generic production costs, with a striking 47% being more than three times higher.14 Similarly, in South Africa, 67% of comparable prices were above the estimated generic price, with 22% exceeding three times the estimated cost.14 Even in India, a major global supplier of generics, 40% of comparable prices were found to be above estimated generic production costs.14 The magnitude of these discrepancies can be extreme, with some specific drugs showing market prices exponentially higher than their estimated production costs; for example, Daclatasvir 30 mg was observed to be 8803 times its estimated price in the UK.14
The significant discrepancies between the low estimated production costs of many essential medicines and their much higher market prices 14 reveal profound market inefficiencies and information asymmetry. Manufacturers often operate with non-transparent cost structures, which severely limits the negotiating power of health systems and procurement agencies.14 This situation suggests that market prices are not solely determined by the actual costs of production but are heavily influenced by the presence of monopolistic pricing, the strength of intellectual property protections, and a general lack of competitive pressure in many markets. This disconnect, where health systems lack crucial data on true production costs, creates an “information asymmetry” 14 that prevents effective price negotiation. This allows manufacturers to charge prices significantly above their marginal production costs, directly contributing to the affordability and access barriers faced by populations globally. Consequently, addressing these price disparities necessitates policies that enhance transparency and foster genuine competition, rather than relying solely on cost-based pricing models which may not adequately reflect the complex market realities.
Table 4: Examples of Price Discrepancies: Estimated Production vs. Market Price for Selected EML Drugs
Drug (Formulation)
Estimated Generic Production Price (USD)
Lowest Available Market Price (USD)
Country
Ratio (Market Price / Estimated Price)
Daclatasvir 30 mg
$0.001
$8.803
UK
8803 14
Daclatasvir 60 mg
$0.001
$5.063
UK
5063 14
Sofosbuvir 400 mg
$0.001
$0.958
UK
958 14
Ledipasvir/Sofosbuvir 90/400 mg FDC
$0.001
$0.593
UK
593 14
Dexamethasone 1.5 mg
$0.0003
$0.116
UK
387 14
Ondansetron 24 mg
$0.006
$0.834
South Africa
139 14
Mercaptopurine 50 mg
$0.001
$0.106
South Africa
106 14
Ondansetron 8 mg
$0.006
$0.54
South Africa
90 14
Omeprazole 40 mg
$0.003
$0.098
South Africa
32.8 14
Haloperidol 2 mg
$0.0004
$0.01
South Africa
25 14
Zidovudine 250 mg
$0.001
$0.045
India
45 14
Praziquantel 150 mg
$0.001
$0.0155
India
15.5 14
Capecitabine 150 mg
$0.001
$0.0138
India
13.8 14
Efavirenz/Emtricitabine/Tenofovir FDC
$0.001
$0.0107
India
10.7 14
Efavirenz 200 mg
$0.001
$0.0105
India
10.5 14
Source:.14 Data represents specific examples of high price discrepancies found in the cited study.
B. Key Factors Influencing Essential Medicine Prices
Intellectual Property Rights (Patents, Regulatory Exclusivities, “Patent Thickets”) Intellectual property (IP) rights, primarily patents and regulatory exclusivities, fundamentally influence the pricing and availability of essential medicines. These rights grant exclusive privileges to inventors, enabling them to charge prices significantly higher than what would be observed in a competitive market.41 This exclusivity is justified as a mechanism for pharmaceutical manufacturers to recoup the substantial investments made in research and development (R&D), including costly clinical trials and regulatory approval processes.41 Patents typically provide protection for 20 years from the filing date, though the effective market exclusivity period after a drug reaches the market is often shorter, ranging from 7-12 years.41 Critics argue that these IP rights, while fostering innovation, also serve to deter or delay competition from generic drug and biosimilar manufacturers, thereby contributing to high drug prices.41 Pharmaceutical companies employ various strategies to extend this exclusivity, including “evergreening”—filing new patents on secondary features of a drug as earlier ones expire—and “product hopping”—shifting the market to new, similar products covered by later-expiring patents.41 The creation of “patent thickets,” which involve amassing numerous overlapping patents on the same pharmaceutical, further deters competition due to the associated risks and high costs of patent litigation.41 Additionally, regulatory exclusivities (e.g., for new chemical entities, orphan drugs, or biologics) also delay the entry of generic and biosimilar alternatives.41 The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) sets minimum standards for IP protection globally, but it also includes flexibilities such as compulsory licensing and parallel imports, which can be used to improve access to medicines.43 However, the practical application of these flexibilities is often met with political and economic pressure against their use.45 Intellectual property rights, while undeniably crucial for incentivizing pharmaceutical innovation and enabling companies to recoup immense R&D costs 41, simultaneously create temporary monopolies that allow for significantly higher-than-competitive prices for essential medicines. This directly impedes affordability and access, particularly in low- and middle-income countries.41 The dramatic price reductions, often ranging from 80-90%, observed after patent expiry due to the entry of generic competitors 44, underscore the profound impact of IP in maintaining high prices during its protected period. This demonstrates that IP acts as a temporary, but substantial, barrier to affordability. The inherent tension between fostering innovation through exclusive rights and ensuring universal access to life-saving medicines necessitates a continuous global policy dialogue aimed at striking a more equitable balance. This includes exploring mechanisms that facilitate earlier generic entry or more effective utilization of TRIPS flexibilities to bridge the access gap for essential medicines.
Market Competition (Generic vs. Patented Drugs, Biosimilars) Market competition, particularly from generic drugs, is a primary driver of price reduction and increased access to medicines following patent expiration.44 Prices can decline dramatically, often by 80-90% within the first year after a patent expires.44 Studies indicate that prices can fall by 20% with the entry of just three generic competitors, and by 70-80% when ten or more competitors enter the market after three years.47 Generic drugs constitute a large volume of prescriptions (e.g., 90% in the US) 47 but account for a comparatively smaller share of total drug costs (e.g., 26% in the US).50 Biosimilars, which are highly similar versions of complex biologic medications, also contribute to price reductions, though their impact is typically more modest (10-30% price decreases) due to their inherent complexity and higher development and regulatory hurdles compared to small-molecule generics.51 However, increased consolidation within the generic drug industry has led to fewer competitors for some drugs, which can slow down the rate of price reduction post-patent expiry.51 While generic competition is the most effective mechanism for driving down prices and expanding access post-patent 44, the generic market itself exhibits significant vulnerabilities. The inherently low profit margins for generics 24 can disincentivize manufacturers, potentially leading to product discontinuations or an underinvestment in quality control and manufacturing infrastructure.38 This economic fragility, further exacerbated by the concentrated nature of global supply chains 24, directly contributes to persistent drug shortages, particularly for essential, low-margin injectable medications.24 This situation presents a complex policy challenge: how to sustain a robust and competitive generic market when the very success of price erosion can undermine manufacturers’ economic incentives to continue production. Ensuring the long-term availability of affordable essential medicines requires not only promoting generic entry but also implementing policies that ensure the economic viability and resilience of generic manufacturing.
Pharmaceutical Supply Chain Dynamics (Concentration, Tariffs, Drug Shortages) Over recent decades, global pharmaceutical supply chains have undergone a significant transformation, moving from predominantly vertically integrated models to horizontally distributed networks. This shift involves outsourcing various functions, such as the production of Active Pharmaceutical Ingredients (APIs) and finished drug products, to multiple firms often concentrated in specific geographical areas.30 This concentration is primarily driven by the pursuit of lower production costs and, in some cases, less stringent regulatory environments.30 However, this over-reliance on a limited number of regions for sourcing critical APIs and other materials introduces substantial risks, significantly increasing the likelihood of drug shortages.24 For example, the United States and India collectively dominate the production of injectable and solid dosage forms, accounting for 45% and 60% of global production, respectively.24 This concentration renders the entire supply chain vulnerable to disruptions originating in these key regions. The imposition of tariffs on pharmaceutical imports can further exacerbate these vulnerabilities by increasing costs for domestic production and distribution, thereby shrinking already slim profit margins for generic drugs and potentially forcing manufacturers to exit the market.24 The consequences of these supply chain dynamics are evident in the record high drug shortages observed, such as the 323 active shortages reported in the US in Q1 2024.25 These shortages are largely attributable to disruptions in the supply chain, an over-reliance on concentrated sourcing (particularly for sole-sourced drugs), and manufacturing quality issues.25 Sterile injectable medicines are especially vulnerable due to their inherent manufacturing complexity and often very low price points.24 Ultimately, drug shortages lead to delayed treatment, force patients onto more expensive alternatives, and place significant strain on healthcare systems.25 The global pharmaceutical supply chain is a complex, interconnected system where cost-driven geographic concentration, trade policies like tariffs, and inherent manufacturing complexities create a web of vulnerabilities that directly translate into drug shortages and inflated prices for essential medicines. The low profit margins characteristic of generic drugs make them particularly susceptible to these disruptions, as manufacturers have reduced incentives to maintain production amidst rising costs or supply shocks.24 This situation underscores that “affordable prices” become meaningless without “available supply,” emphasizing that supply chain resilience must be considered a core component of ensuring access to essential medicines. Without a stable and secure supply, discussions about low production costs or negotiated prices lose their practical relevance, highlighting the urgent need for strategies that prioritize resilience alongside cost efficiency.
National Healthcare Policies and Reimbursement Models (e.g., Price Negotiation, Rebates, Formularies) National governments implement a variety of policies and reimbursement models with the overarching goal of achieving affordable and equitable access to quality-assured pharmaceutical products.53 Price Negotiation: Policies such as the Inflation Reduction Act (IRA) in the United States empower Medicare to negotiate prices for certain drugs, a measure projected to generate billions in savings.54 Expanding the scope of such negotiation could potentially yield over $1 trillion in system-wide savings over a decade.54 These negotiated prices can be significantly lower than initial list prices, with Medicare achieving discounts ranging from 38% to 79%.54 Public scrutiny and Medicare’s negotiation efforts have already demonstrated an ability to drive down prices for some drugs, as seen with Eli Lilly’s insulin.54 Rebates: Drug manufacturers are often required to provide mandatory rebates to government programs like Medicaid.54 The Affordable Care Act (ACA), for instance, expanded Medicaid and increased these mandatory rebates, resulting in billions in costs for manufacturers.56 However, rebates negotiated by Pharmacy Benefit Managers (PBMs) can paradoxically inflate list prices, with a $1 increase in rebates often associated with a $1.17 increase in list price.55 PBMs wield significant market power, controlling a large share of the US drug market (e.g., 80%).57 Formularies: Healthcare payers utilize formularies, which are lists of covered drug products categorized into tiers with varying levels of patient cost-sharing.58 These formularies serve as tools for payers to select among treatment options, often securing rebates from drug manufacturers in exchange for preferred formulary placement.58 Unintended Consequences: While intended to control costs and improve access, national healthcare policies can have complex and sometimes unintended consequences on drug pricing and manufacturer behavior.55 For example, policies that impose mandatory rebates or new taxes on manufacturers, such as those under the ACA, can reduce manufacturers’ revenues or increase their operating costs.56 In response, manufacturers may raise list prices to offset these losses, effectively shifting costs elsewhere in the healthcare system.55 Similarly, overly aggressive price controls can disincentivize pharmaceutical innovation or lead to drug shortages if profit margins become unsustainable for manufacturers, particularly for generic drugs.55 Low prices, if they result in insufficient profit margins, can cause unavailability, supply interruptions, or shortages of essential medicines.53 National healthcare policies, while designed to control costs and improve access 53, operate within a complex adaptive system and can trigger intricate and sometimes counterproductive responses from the pharmaceutical industry.55 Policies that impose financial burdens on manufacturers, such as increased Medicaid rebates or new taxes (as seen with the ACA) 56, can lead them to raise list prices to compensate for lost revenue, thereby shifting the cost burden to other payers or patients. Similarly, aggressive price controls, while seemingly beneficial, risk undermining the economic viability of drug production, particularly for low-margin generics.55 This can result in manufacturers reducing investment in R&D, exiting markets for unprofitable drugs, or even causing drug shortages.53 The dynamics of PBMs, where their profit motives tied to rebates can inflate list prices, further illustrate how mechanisms intended to lower net costs can have adverse effects on overall pricing transparency and affordability.57 This highlights the critical need for nuanced policy design that carefully balances the immediate goal of affordability with the long-term imperatives of sustainable supply, robust quality, and continued innovation. A holistic understanding of these interdependencies is essential to avoid unintended consequences that could ultimately compromise patient access to essential medicines.
V. Strategies to Enhance Affordability and Access to Essential Medicines
A. Procurement and Purchasing Mechanisms (Bulk Purchasing, Pooled Procurement)
Mechanisms Bulk purchasing leverages the collective buying power of large volumes to negotiate lower unit prices, often directly with manufacturers.61 The savings achieved through this method tend to increase proportionally with the volume purchased.61 Pooled procurement extends this concept by aggregating buying power across multiple purchasers, either within a single country (intra-country) or across several countries (inter-country).57 This creates a “monopsony”—a market condition where market dynamics are driven by major buyers—enabling stronger negotiation terms.63 This approach is particularly beneficial for smaller countries that may struggle to meet minimum order quantities and for larger countries when procuring small-volume, high-cost commodities like oncology drugs.63
Examples The Vaccines for Children (VFC) Program in the US is a notable example, where the Centers for Disease Control and Prevention (CDC) centralizes the purchase of childhood vaccines. By leveraging its significant market power (purchasing over 40% of US childhood vaccines), the CDC secures reduced prices.62 Similarly, multistate Medicaid drug purchasing pools in the US allow states to combine their Medicaid drug purchasing, increasing their market power to secure greater discounts.62 Innovative approaches include subscription-based purchasing for Hepatitis C cures in Louisiana and Washington State, where a flat, negotiated fee grants access to an increased supply of a drug over a period, significantly improving patient access while maintaining or reducing state spending.62 Internationally, the Pneumococcal Vaccine Advanced Market Commitment (AMC), managed by GAVI, guaranteed a viable market for manufacturers, leading to substantial price reductions (up to 90%) and incentivizing increased production capacity.65
Benefits These procurement strategies yield numerous benefits, including lower unit prices, reduced supply chain and administrative costs, the promotion of standardized treatment guidelines, harmonized drug registration and quality assurance, increased access to commodities, improved forecast accuracy, and even increased sales revenue for manufacturers by opening up previously “out of reach” markets.63
Risks Despite the advantages, these mechanisms carry inherent risks, such as potentially reduced access to some drugs, a limited number of suppliers that could lead to monopolies, increased administrative overheads, and the complexity of establishing new supply channels.61
Bulk purchasing and pooled procurement are not merely cost-saving tactics but powerful market-shaping tools.63 These mechanisms extend beyond simply securing discounts; they actively reshape market dynamics by providing manufacturers with crucial demand visibility and reducing their financial risks (e.g., through volume guarantees).65 By mitigating the uncertainty of sales volumes, these strategies can incentivize manufacturers to invest in increased production capacity, leading to lower unit costs through economies of scale, and ensuring a more stable supply.65 Furthermore, by guaranteeing a viable market, these approaches can even stimulate research and development (R&D) for neglected diseases or for products that might otherwise be deemed commercially unviable.65 This transforms the challenge of access from a purely procurement-focused issue to a broader strategy of market development. However, it is important to acknowledge the potential for reduced supplier competition and increased administrative complexity 61, which necessitates careful design and implementation to avoid unintended consequences such as new monopolies or undue administrative burdens that could undermine long-term supply stability.
B. Innovative Financing Models (Volume Guarantees, Debt/Loan Guarantees)
Innovative finance models are designed to bridge critical gaps in development funding, attracting additional capital and leveraging existing resources to achieve global health objectives.65 These mechanisms focus on de-risking the market for manufacturers, thereby incentivizing the production and distribution of essential medicines.
Volume Guarantees Volume guarantees are structured to mitigate the risks faced by manufacturers due to uncertain sales volumes in specific markets.65 In exchange for a guaranteed volume of sales, manufacturers commit to offering lower prices and ensuring stable supply. Organizations like MedAccess enter into legally binding agreements to guarantee these sales volumes, with manufacturers committing to a ceiling price and meeting projected demand. If actual sales fall short of the guaranteed levels, the guaranteeing entity compensates the manufacturer for the shortfall.66 This model builds confidence, encouraging manufacturers to enter or expand in uncertain markets and scale up production, while procurers benefit from predictable prices and supply. For instance, a volume guarantee for contraceptive implants led to a 53% price reduction and a significant increase in demand.65
Procurement Guarantees Procurement guarantees serve to bridge the financial gap between when an order for medical products is placed and when the funds are actually received.66 This allows global health procurers to respond more rapidly to country needs and to enter into high-volume purchase agreements, securing preferential terms and allocations. These guarantees provide procurers with the confidence to realize potential demand and operate at a greater capacity, ultimately leading to improved value for money, reduced lag times, and enhanced quality assurance for end purchasers.66
Debt Finance Entities like MedAccess provide debt finance to suppliers who need to make investments to expand the supply of critical medical products at affordable prices.66 This is particularly valuable when commercial lenders perceive a project as too risky, making it difficult for healthcare manufacturers to access conventional capital. This debt financing is strategically deployed to support businesses committed to expanding access and achieving sustainable impact, often with the condition that the funds are used to improve affordability.66
Loan Guarantees Loan guarantees enhance a supplier’s credit profile by guaranteeing their payment obligations under a loan from commercial lenders.66 This can lead to more favorable loan terms, enabling investments that expand access to healthcare products and services at affordable prices.66
Other prominent examples of innovative finance in global health include GAVI, the Global Fund, and the Affordable Medicines Fund for Malaria.65 GAVI’s International Finance Facility for Immunisation (IFFIm), for instance, has raised nearly $8 billion for vaccine programs, accelerating high-volume procurement at lower prices.67
The core strategic element of innovative financing models is their ability to fundamentally shift the focus from simply negotiating lower prices to proactively de-risking the market for manufacturers.65 By guaranteeing volumes or providing financial assurances, these mechanisms reduce the perceived commercial risk associated with investing in research and development, scaling up production, or entering uncertain low-income markets. This de-risking incentivizes manufacturers to produce essential medicines at lower unit costs, as they can confidently plan for economies of scale and a predictable return on investment. This approach transforms what might otherwise be considered market failures into viable commercial opportunities, ultimately ensuring a more stable supply and improving affordability and access for populations in need.
C. Technology Transfer and Local Manufacturing Capacity Building
Technology transfer is a critical process involving the systematic transfer of knowledge, skills, methods, and data from the drug discovery and early R&D phases to large-scale commercial manufacturing.68 Its primary objective is to ensure consistency, maintain quality, and achieve compliance with stringent regulatory standards throughout the scale-up process.68 An efficient technology transfer process can significantly reduce both time and costs by identifying and resolving potential production issues early in the development cycle.68
Challenges Despite its importance, technology transfer in pharmaceutical manufacturing faces several formidable challenges. These include inherent technological complexities, such as the difficulties in scaling up processes from lab-scale to commercial production, which can reveal unforeseen differences in equipment, process variability, or material handling.68 Effective communication barriers between the transferring and receiving entities can lead to errors, delays, and costly rework.68 Furthermore, a lack of adequate local ecosystems, including insufficient R&D capacities, a shortage of specialized work teams, limited technological resources, and inadequate recognition of Good Manufacturing Practices (GMP), can significantly impede successful technology transfer.71
Solutions/Trends To overcome these challenges, several solutions and trends are emerging. The increasing adoption of digitalization and automation tools is streamlining the transfer process by improving data accuracy, reducing human error, and enabling real-time monitoring of production processes.68 The globalization of manufacturing necessitates adapting to diverse regional and cultural contexts, which in turn promotes the development of standardized processes and guidelines to ensure consistent product quality across multiple sites.68 Crucially, supportive policy frameworks are essential to facilitate these complex transfers and foster the necessary local capabilities.71
Effective technology transfer and the strategic building of local manufacturing capacity are crucial for improving access to essential medicines. This is achieved not solely by potentially lowering production costs, but, more importantly, by enhancing regional supply chain resilience and reducing over-reliance on a few concentrated global sources.68 By empowering diverse manufacturers, particularly in low- and middle-income countries, to produce essential medicines locally, technology transfer directly mitigates the risks associated with geopolitical shocks, trade disruptions, and single-source dependencies that frequently contribute to drug shortages.24 This approach transforms access from primarily a procurement challenge to one of localized production capability. Ultimately, this localization can foster regional competition, potentially leading to more stable and affordable prices over the long term by reducing transportation costs and insulating against external supply shocks. It fundamentally shifts the paradigm from simply importing essential medicines to strategically producing them where they are most needed, thereby directly addressing critical access barriers related to both availability and affordability.
D. Policy Interventions and Regulatory Reforms (e.g., Transparency, Incentives for Quality)
Effective policy interventions for essential medicines demand a holistic and integrated approach that extends beyond simplistic price controls. These interventions must address systemic issues across the entire pharmaceutical ecosystem.
Transparency Advocating for greater transparency in drug pricing, clinical trial data, public funding contributions, and R&D costs is paramount.72 Public disclosure of this information can significantly reduce information asymmetry, thereby empowering negotiators and enabling more equitable price negotiations.14
Incentives for Quality Public and private drug purchasers should implement payment and purchasing models that explicitly incentivize supply chain quality, resilience, and the maintenance of reserves for drugs vulnerable to shortages.24 This requires the development and application of objective metrics for assessing quality and resilience throughout the supply chain.24
Regulatory Streamlining Streamlining regulatory processes to facilitate the entry of new manufacturers into the market is crucial.25 The FDA’s Abbreviated New Drug Application (ANDA) process, for instance, already serves to expedite generic drug approval.44 Further efforts in this area can enhance competition.
Government Intervention in Supply Governments have a vital role in encouraging local drug production to reduce over-reliance on overseas manufacturers.25 This can be complemented by implementing stricter regulations to prevent price gouging and actively fostering competition within the domestic market.25
Addressing Intellectual Property Barriers More effective utilization of TRIPS flexibilities, such as compulsory licensing and parallel imports, is essential to overcome intellectual property barriers that impede access to affordable medicines.43
Linking Outcomes to Expenditures Leveraging real-world clinical data to evaluate the true value of pharmaceutical products can inform policy decisions, potentially leading to cost savings and identifying further opportunities for policy action.54
Effective policy interventions for essential medicines require a comprehensive and integrated approach that moves beyond narrow price controls to address systemic issues across the entire pharmaceutical ecosystem. This necessitates fostering greater market transparency, incentivizing quality and resilience throughout the supply chain (e.g., through payment models that reward quality) 24, actively promoting robust competition (particularly for generics and biosimilars) 55, and strategically leveraging public-private partnerships and technology transfer to build local manufacturing capacity.71 A singular focus on price alone risks triggering unintended consequences, such as drug shortages or stifled innovation.55 The pharmaceutical market is a complex adaptive system 59, meaning that interventions must anticipate potential industry responses. The goal should be to balance affordability with the long-term sustainability of drug supply and innovation. This integrated approach is essential to address the root causes of access barriers and ensure a consistent supply of affordable, high-quality essential medicines.
VI. Conclusion and Recommendations
The comprehensive analysis of the estimated costs of production and potential prices for the WHO Essential Medicines List reveals a complex economic landscape. While many essential medicines can be manufactured at remarkably low costs, systemic factors often inflate their market prices and impede equitable access. This disparity is driven by a multifaceted interplay of intellectual property rights, the dynamics of global supply chains, and national healthcare policies. The increasing complexity and inclusion of high-cost biologics on the EML further exacerbate these challenges, demanding a nuanced understanding beyond traditional generic cost models. Market inefficiencies, information asymmetry, and the inherent fragility of low-margin generic supply chains contribute significantly to price discrepancies and persistent drug shortages. Achieving truly affordable and equitable access to the WHO Essential Medicines List requires a coordinated, multi-stakeholder approach that addresses these market failures, leverages collective power, and builds resilient, high-quality supply chains globally.
Based on this analysis, the following recommendations are put forth to enhance affordability and access to essential medicines:
Enhance Price Transparency: Advocate for the public disclosure of production costs and comprehensive pricing data across the pharmaceutical value chain. This will reduce information asymmetry, empower health systems in price negotiations, and foster a more competitive environment.14
Strengthen Procurement Mechanisms: Promote and expand the adoption of bulk purchasing and pooled procurement strategies. Implement innovative financing models, such as volume guarantees and procurement guarantees, to leverage collective buying power and mitigate financial risks for manufacturers, thereby incentivizing production and lower unit costs through economies of scale.62
Foster Robust Generic and Biosimilar Competition: Implement policies that expedite the entry of generic and biosimilar products following patent expiry. Continuously monitor market consolidation to prevent anti-competitive practices that could limit competition and slow price erosion.44
Build Supply Chain Resilience: Incentivize the geographic diversification of pharmaceutical manufacturing facilities and promote manufacturing redundancies for critical medicines. Encourage investment in advanced production technologies, such as continuous manufacturing, to enhance efficiency and mitigate the risks of supply disruptions and shortages.24
Invest in Local Manufacturing and Technology Transfer: Support the development and strengthening of local production capacities, particularly in low- and middle-income countries. This requires targeted technology transfer programs, comprehensive ecosystem development (including R&D capabilities, skilled workforce, and robust regulatory frameworks), and policy support.68
Align Policy Incentives: Design national healthcare policies and reimbursement models to carefully balance the goals of affordability with the imperatives of sustainable supply, quality, and innovation. Policies should avoid unintended consequences that could lead to drug shortages or stifle necessary R&D, recognizing the complex interplay within the pharmaceutical ecosystem.53
Prioritize Quality in Procurement: Integrate transparent quality designations and metrics into procurement processes. This will incentivize manufacturers to maintain high quality standards throughout the supply chain, recognizing that initial cost savings achieved by compromising quality can lead to significantly higher long-term costs due to recalls, failures, and shortages.24
By implementing these integrated strategies, global health stakeholders can move closer to ensuring that the essential medicines identified by the WHO are not only clinically effective but also consistently available and truly affordable for all populations.
CONTINUOUS MANUFACTURING FOR THE MODERNIZATION OF PHARMACEUTICAL PRODUCTION: PROCEEDINGS OF A WORKSHOP – NCBI, accessed July 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK540224/
